- Home
- CURX vs APM Comparison
CURX vs APM Comparison
Compare CURX & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CURX | APM |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 8.0M |
| IPO Year | 2025 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CURX | APM |
|---|---|---|
| Price | $0.28 | $0.72 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.7M | 66.2K |
| Earning Date | 09-09-2025 | 10-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.61 | $0.69 |
| 52 Week High | $8.60 | $4.47 |
Technical Indicators
Market Signals| Indicator | CURX | APM |
|---|---|---|
| Relative Strength Index (RSI) | 32.40 | 41.72 |
| Support Level | $0.27 | $0.80 |
| Resistance Level | $0.31 | $0.88 |
| Average True Range (ATR) | 0.03 | 0.08 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 11.45 | 39.89 |
Price Performance
Historical ComparisonAbout CURX Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.